Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
Canadian Cancer Trials Group
Canadian Cancer Trials Group
SWOG Cancer Research Network
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Centre Antoine Lacassagne
National Institutes of Health Clinical Center (CC)
Institut Bergonié
Universität des Saarlandes
European Organisation for Research and Treatment of Cancer - EORTC
National Institutes of Health Clinical Center (CC)
SWOG Cancer Research Network
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Mayo Clinic
University of Nebraska
M.D. Anderson Cancer Center
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Memorial Sloan Kettering Cancer Center
University of Nebraska
H. Lee Moffitt Cancer Center and Research Institute
Alliance for Clinical Trials in Oncology
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Celgene
Weill Medical College of Cornell University
SWOG Cancer Research Network
National Institutes of Health Clinical Center (CC)
Mesoblast, Ltd.
SWOG Cancer Research Network
Seagen Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Universität des Saarlandes
Alliance for Clinical Trials in Oncology
Universität des Saarlandes
Universität des Saarlandes
Universität des Saarlandes
German High-Grade Non-Hodgkin's Lymphoma Study Group
UNICANCER
European Organisation for Research and Treatment of Cancer - EORTC
SWOG Cancer Research Network
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Hoffmann-La Roche
Stanford University
Eli Lilly and Company
M.D. Anderson Cancer Center